Power3 Medical Products, Inc. CEO Helen R. Park Interviewed by Wall Street Transcript

Provided company update on commercialization of NuroPro® CLIA Test

Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced today that the company’s CEO, Helen R. Park, M.S. was interviewed by the Wall Street Transcript, TWST, an on line magazine on Wednesday of last week.

Ms. Park provided a company update on the state of the clinical trials for Neurodegenerative disease diagnostic tests and for breast cancer diagnostic tests. Specifically, she discussed the progress of the NuroPro® AD and NuroPro® PD clinical trials. Power3 has finished Phase I and reported the results at the International Congress of Alzheimer’s Disease (ICAD) in Vienna, Austria on July 14 2009. This was accomplished with the support of Power3’s licensee and collaborator for NuroPro, Transgenomic, Inc. Omaha, Nebraska and despite the huge impact on Power of the world economic down turn and Hurricane Ike. Ms. Park re-structured the company by reducing the burn rate, and re-focused the commercialization on the completion of the NuroPro® Phase I clinical trials by executing the license and collaboration agreement with Transgenomic, and expanding Power3’s Scientific Board to complement renowned neurologist, Dr. Stan Appel and provide additional expertise, representation and inroads in Alzheimer’s disease (Dr Marwan Sabbagh), Parkinson’s disease (Dr. Katerina Markopoulou), psychiatric diseases (Dr. Lourdes Bosquez), and gastro intestinal diseases (Dr. Eric Zuckerman). Sources for additional funding via direct investment were also obtained.

“This interview was a great opportunity to provide the newest information on not only our testing and but also the progress in our facing the economic situation”, commented Ms. Helen R. Park, CEO of Power3. “We were able to overcome this and recover from the damage done during hurricane IKE. This progress is thanks to our licensing agreement with Transgenomic, Inc. and the diligence of our staff at Power3. We are now moving to the Phase II, prospective samples for Alzheimer’s and Parkinson’s.”

“The fact that we have progressed so far under difficult circumstances underscores the viability of our technology and the tenacity of our people at Power3,” commented Ira L. Goldknopf, President and CSO. “To be able to present our unique and breakthrough clinical validation results at ICAD, the Alzheimer’s Disease Association’s annual meeting was an honor for me and great exposure for the company to the worldwide community of neurologists. It’s terrific to be working with Helen!”

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (OTCBB:PWRM) (www.Power3Medical.com), is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Contact:
Power3 Medical Products, Inc.
CEO
Helen R. Park, M.S.
hpark@power3medical.com
www.power3medical.com

Source: Power3 Medical Products, Inc.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for the completion of building a website for Power 3 Medical Products Inc. (PWRM.OB)

Last 5 posts by Stock-PR

• Stock-PR Pink Sheet Stock Headlines September 15, 2009 - September 15th, 2009
• Power3 Medical Products Inc. CEO Interview: Helen R. Park - September 15th, 2009
• NWMT, NewMarket Technology, Inc. Signs LOI in China for 3rd Major Outsourcing Opportunity This Year to Add to $65 Million in Recent Contracts and Bolstering $100 Million Forecast - September 15th, 2009
• Consorteum Holdings Inc. Forms Joint Venture to Capitalize on Emerging International Markets - September 15th, 2009
• NewMarket Technology, Inc. Eyes East Africa to Expand Its Nearly $100 Million in Global Sales - September 15th, 2009